학술논문
Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
Document Type
article
Author
Francisca Sivera; Victoria Núñez-Monje; Cristina Campos-Fernández; Isabel Balaguer-Trull; Montserrat Robustillo-Villarino; Marta Aguilar-Zamora; Marta Garijo-Bufort; Juan Miguel López-Gómez; Carolina Peña-González; Isabel de la Morena; Diego Bedoya-Sanchís; Liliya Yankova-Komsalova; Arantxa Conesa-Mateos; Anna Martínez-Cristóbal; Francisco Javier Navarro-Blasco; José Miguel Senabre-Gallego; Juan José Alegre-Sancho
Source
Frontiers in Medicine, Vol 10 (2023)
Subject
Language
English
ISSN
2296-858X
Abstract
BackgroundSecukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical practice is still limited. Here, we aimed to provide real-world data on secukinumab use, effectiveness, and persistence in axSpA.Patients and methodsRetrospective, multicenter study of patients with a diagnosis of axSpA treated with secukinumab at 12 centers up to June 2021 in the Valencian Community (Spain). Information was gathered on BASDAI measurement, pain, patient and physician global assessment (ptGA, phGA) using a 100-mm visual analog scale (VAS), persistence and other secondary variables by treatment line (first, second, and ≥ third) for up to 24 months.Results221 patients were included (69% men; mean age [standard deviation, SD]: 46.7 [12.1] years old). Secukinumab was used as a first-line bDMARD in 38% of patients, as a second-line in 34% and as a ≥ hird-line in 28%. The percentage of patients achieving low disease activity (BASDAI